ArticleBMC medical imaging2025
Enhancing risk stratification in diabetic gastric cancer: muscle-fat ratio from photon-counting CT as a predictor of postoperative complications.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIn diabetic gastric cancer patients, body composition (skeletal muscle–to–fat ratio, MFR) may influence surgical outcomes. We evaluated whether Photon-counting CT (PCD-CT) derived MFR predicts major postoperative complications, reflecting its value in perioperative risk stratification.
methodsA retrospective analysis of 134 gastric cancer patients with type 2 diabetes was conducted. Preoperative PCD-CT scans assessed body composition. Logistic regression models identified predictors of poor postoperative outcomes, defined by major postoperative complications. The predictive accuracy of models incorporating clinical variables and MFR was evaluated using receiver operating characteristic curves, integrated Discrimination Improvement (IDI), and net Reclassification Improvement (NRI).
resultsPatients who developed major complications (n = 35) had significantly lower skeletal muscle area (45.5 vs. 56.2 cm²; P < 0.01) and higher fat accumulation. Abnormal MFR (0.34–0.57)was a strong predictor of poor outcomes (OR = 1.94, 95% CI: 1.17–2.58, p < 0.01) compared to patients without complications (n = 99). The model combining clinical variables with MFR had the best performance (AUC = 0.75, sensitivity = 0.74, specificity = 0.71) in predicting major complications, outperforming a model based solely on clinical factors. It also showed substantial improvements in predictive accuracy, with an NRI of 0.52 (p < 0.01) and an IDI of 0.09 (p < 0.01).
conclusionMFR, quantified by PCD-CT, is a reliable and accurate biomarker for identifying diabetic gastric cancer patients at higher risk of major postoperative complications. MFR demonstrates strong predictive value for adverse surgical outcomes, reinforcing its role in perioperative risk stratification. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.